A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment

• Status: Not yet recruiting
• Trial end date: 2024-11-30
• Target enrollment: 0
• Participant gender: All

Summary

This is a multi-center, randomized, double-blind, placebo-controlled, Phase IV trial to evaluate the efficacy and safety of Choline Alfoscerate compared to placebo in patients with degenerative mild cognitive impairment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chong Kun Dang Pharmaceutical
• Collaborator: Choline Alfoscerate Re-evaluation Consortium (57 pharmaceutical companies)
• Treatments: Choline

Criteria

Inclusion Criteria:

1. Age ≥ 55 years

2. Diagnosis of mild cognitive impairment due to Alzheimer's disease that meets NIA-AA criteria

3. Diagnosed with mild cognitive impairment on SNSB

4. Delayed recall score of SVLT ≤ "average -1.5 standard deviation"

5. K-MMSE-2 score ≥ 24

6. The CDR score 0.5, and the memory item score 0.5 or 1 point

7. Patients with caregivers who are in regular contact, can visit together

8. Walk or move using walking aids (i.e., walkers, walking sticks or wheelchairs)

9. Sufficient vision, hearing, language skills, motor skills, and understanding to follow the examination procedure.

10. Written informed consent

Exclusion Criteria:

1. Diagnosis of dementia (including secondary dementia due to Alzheimer's disease, vascular dementia, infections of the central nervous system (e.g., HIV, syphilis, Creutzfeld-Jacob disease), Pixie disease, Huntington's disease, Parkinson's disease, etc.)

2. Medication of dementia within the past three months

3. Brain functional improvement medication in the past six weeks.

4. Medication that may affect cognitive function during clinical trials

5. No studies (no regular school entrance), illiteracy

6. Significant neurological conditions (such as stroke, multiple sclerosis, severe head trauma with loss of consciousness, cerebral palsy, cerebral tumor, cerebral infarction, spinal infarction or central nervous system infection) and/or evidence (CT or MRI results performed within the past 12 months or during screening)

7. Abnormal results from Vitamin B12, Thyroid Stimulated Hormone Test (TSH), HIV-Ab, and VDRL test contribute to or contribute to cognitive impairment of the subject

8. Serious mental disorders such as severe depression, schizophrenia, alcoholism, drug dependence, etc.